PP
MLNT

Paloma Partners’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Paloma Partners’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-30,800
Closed -$205K – 2436
2019
Q2 		$205K Buy
+30,800
New +$117K ﹤0.01% 1536

Other funds holding MLNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Paloma Partners's MLNT Position: Q3 2019 in Review

Paloma Partners sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 30,800 shares — an estimated $205K sold.

Paloma Partners first reported a position in MLNT in Q2 2019 and held it in 1 quarter. The position peaked at $205K in Q2 2019. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

  • Paloma Partners reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 30,800 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $205K.
  • Paloma Partners first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Paloma Partners's Melinta Therapeutics, Inc. Common Stock position peaked at $205K in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.